PTC Therapeutics PTCT Stock
PTC Therapeutics Price Chart
PTC Therapeutics PTCT Financial and Trading Overview
PTC Therapeutics stock price | 33.93 USD |
Previous Close | 43.01 USD |
Open | 42.79 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 800 |
Day's Range | 42.49 - 44.01 USD |
52 Week Range | 27.09 - 59.84 USD |
Volume | 479.57K USD |
Avg. Volume | 857.19K USD |
Market Cap | 3.23B USD |
Beta (5Y Monthly) | 0.421126 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.69 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52.93 USD |
PTCT Valuation Measures
Enterprise Value | 4.4B USD |
Trailing P/E | N/A |
Forward P/E | -13.939104 |
PEG Ratio (5 yr expected) | 1.08 |
Price/Sales (ttm) | 4.187893 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 5.717 |
Enterprise Value/EBITDA | -14.072 |
Trading Information
PTC Therapeutics Stock Price History
Beta (5Y Monthly) | 0.421126 |
52-Week Change | 53.07% |
S&P500 52-Week Change | 20.43% |
52 Week High | 59.84 USD |
52 Week Low | 27.09 USD |
50-Day Moving Average | 50.45 USD |
200-Day Moving Average | 46.28 USD |
PTCT Share Statistics
Avg. Volume (3 month) | 857.19K USD |
Avg. Daily Volume (10-Days) | 626.7K USD |
Shares Outstanding | 74.19M |
Float | 65.32M |
Short Ratio | 5.89 |
% Held by Insiders | 2.60% |
% Held by Institutions | 106.44% |
Shares Short | 6.34M |
Short % of Float | 11.65% |
Short % of Shares Outstanding | 8.55% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -74.14% |
Operating Margin (ttm) | -59.49% |
Gross Margin | 1.78% |
EBITDA Margin | -40.62% |
Management Effectiveness
Return on Assets (ttm) | -16.80% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 770.45M USD |
Revenue Per Share (ttm) | 10.65 USD |
Quarterly Revenue Growth (yoy) | 48.19% |
Gross Profit (ttm) | 2.63M USD |
EBITDA | -313028000 USD |
Net Income Avi to Common (ttm) | -571249984 USD |
Diluted EPS (ttm) | -7.78 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 286.3M USD |
Total Cash Per Share (mrq) | 3.86 USD |
Total Debt (mrq) | 1.46B USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.389 |
Book Value Per Share (mrq) | -6.182 |
Cash Flow Statement
Operating Cash Flow (ttm) | -288740992 USD |
Levered Free Cash Flow (ttm) | -257165872 USD |
Profile of PTC Therapeutics
Country | United States |
State | NJ |
City | South Plainfield |
Address | 100 Corporate Court |
ZIP | 07080 |
Phone | 908 222 7000 |
Website | https://www.ptcbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 1402 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Q&A For PTC Therapeutics Stock
What is a current PTCT stock price?
PTC Therapeutics PTCT stock price today per share is 33.93 USD.
How to purchase PTC Therapeutics stock?
You can buy PTCT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PTC Therapeutics?
The stock symbol or ticker of PTC Therapeutics is PTCT.
Which industry does the PTC Therapeutics company belong to?
The PTC Therapeutics industry is Biotechnology.
How many shares does PTC Therapeutics have in circulation?
The max supply of PTC Therapeutics shares is 76.7M.
What is PTC Therapeutics Price to Earnings Ratio (PE Ratio)?
PTC Therapeutics PE Ratio is now.
What was PTC Therapeutics earnings per share over the trailing 12 months (TTM)?
PTC Therapeutics EPS is -7.69 USD over the trailing 12 months.
Which sector does the PTC Therapeutics company belong to?
The PTC Therapeutics sector is Healthcare.
PTC Therapeutics PTCT included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16770.21 USD — |
+0.17
|
7.15B USD — | 16726.57 USD — | 16793.92 USD — | — - | 7.15B USD — |
NASDAQ Global Select Market Com NQGS | 8148.16 USD — |
-0.03
|
— — | 8138.77 USD — | 8178.26 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 20358.19 USD — |
-0.02
|
— — | 20335.08 USD — | 20432.27 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1438.97 USD — |
-0.5
|
— — | 1436.63 USD — | 1444.16 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2645 USD — |
-0.56
|
— — | 2643.93 USD — | 2659.02 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4442.6 USD — |
-0.3
|
— — | 4414.3 USD — | 4453.46 USD — | — - | — — |
NASDAQ HealthCare IXHC | 1000.09 USD — |
-0.34
|
— — | 995.62 USD — | 1002.05 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4775.05 USD — |
-0.19
|
— — | 4743.29 USD — | 4785.33 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2167.14 USD — |
-0.32
|
— — | 2164.33 USD — | 2172.59 USD — | — - | — — |
- {{ link.label }} {{link}}